

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/522,911
Sheet	1	of	2	Filing Date	July 7, 2005
				First Named Inventor	Senter, Peter D.
				Art Unit	1654
				Examiner Name	Christina Bradley
				Attorney Docket Number	018891-004310US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (<i>if known</i>)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³	Number ⁴ Kind Code ⁵ (<i>if known</i>)				
1.	WO	02/43661	A2, A3	06-06-2002	Seattle Genetics, Inc.		<input type="checkbox"/>
2.	WO	02/088172	A	11-07-2002	Seattle Genetics Inc.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²
	3.	CARTER, P.J. et al., "Antibody-Drug Conjugates for Cancer Therapy," <i>The Cancer Journal</i> , May/June 2008, Vol. 14, No. 3, pp. 154-169.					<input type="checkbox"/>
	4.	DORONINA, S.O. et al., "Potent Monoclonal Antibody-Drug Conjugates: The Role of Linker Stability in Efficacy, Toxicity and Specificity," poster #6425 at the annual meeting of the American Association for Cancer Research, AACR, Toronto, Ontario, CA, April 5-9, 2003.					<input type="checkbox"/>
	5.	FRANCISCO, J.A. et al., "SGN-35, an Anti-CD30 Antibody-Drug Conjugate with Potent Antitumor Activity," poster #770 at the annual meeting of the American Association for Cancer Research, AACR, Toronto, Ontario, CA, April 5-9, 2003.					<input type="checkbox"/>
	6.	GARTEIZ, D.A. et al., "Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase 1 clinical trial," <i>Cancer Chemother. Pharmacol.</i> , 1998, Vol. 41, pp. 299-306.					<input type="checkbox"/>
	7.	HAMANN, P.R. et al., "Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia," <i>Bioconjugate Chem.</i> , 2002, Vol. 13, No. 1, pp. 47-58.					<input type="checkbox"/>
	8.	MEYER, D. et al., "Proteolytic vs. Hydrolytic Released Drug from Anti-Tumor Immunochemotherapeutic Agents." poster presentation at Gordon Research Conference on Drug Carriers In Medicine & Biology, February 24 - March 1, 2002, Ventura, California, USA					<input type="checkbox"/>
Examiner Signature					Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/522,911
				Filing Date	July 7, 2005
				First Named Inventor	Senter, Peter D.
				Art Unit	1654
				Examiner Name	Christina Bradley
Sheet	2	of	2	Attorney Docket Number	018891-004310US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	9.	Office Action mailed on March 26, 2008, for U.S. Patent Application No. 10/496,628, filed on December 17, 2004, 19 pages.		
	10.	Restriction Requirement mailed on March 3, 2009, for U.S. Patent Application No. 10/558,811, filed on February 5, 2007 8 pages.		
	11.	SENTER, P. et al., "Cures and Regressions of Established Tumors with Monoclonal Antibody-Auristatin E Conjugates." poster presentation at the annual meeting of the American Association for Cancer Research, April 6-10, 2002, San Francisco, California, USA		
	12.	Supplementary European Search Report for EP Application No. 03772186.7, filed on July 31, 2003, 2 pages.		
	13.	VERDIER-PINARD, P. et al., "Sustained Intracellular Retention of Dolastatin 10 Causes Its Potent Antimitotic Activity," <i>Molecular Pharmacology</i> , 2000, Vol. 57, pp. 180-187.		
	14.	WAHL, A.F. et al., "Anti-Cancer Activity of High Potency Anti-CD20 Antibody-Drug Conjugates," poster #769 at the annual meeting of the American Association for Cancer Research, AACR, Toronto, Ontario, CA, April 5-9, 2003.		
				T ²

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.